Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion

American Journal of Health-System Pharmacy

Volumn 54, Issue 6, 1997, Pages 683-686

  Owens, Dwight ^a,b   Fleming, Ronald A ^c   Restino, Maryann S ^a   Cruz, Julia M ^d   Hurd, David D ^d,e  

^a NE Tennessee Rehabilitation Center ^*

^b North Carolina Baptist Hospital   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Department of Internal Medicine   (United States)

^e Bone Marrow Transplant Program

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DILUENT; GLUCOSE; LIPID EMULSION; NAPHTHALENE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG INCOMPATIBILITY; DRUG MIXTURE; DRUG STABILITY; PRIORITY JOURNAL;

EID: 0031004231     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.6.683     Document Type: Article

References (18)

1. Khoo SH, Bond J, Denning DW. Administering amphotericin B - a practical approach. J Antimicrob Chemother. 1994; 33:203-13.
2. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990; 5:94-108.
3. Moreau P, Milped N, Fayetts N et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992; 30:535-41.
4. Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm. 1992; 49:1156-64.
5. Caillot D, Casasnovas O, Solary E et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother. 1993; 31:161-9.
6. Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health-Syst Pharm. 1995; 52:1463-4. Letter.
7. Lopez RM, Ayestaran A, Pou L et al. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. Am J Health-Syst Pharm. 1996; 53:2724-7.
8. Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. Am J Hosp Pharm. 1991; 48:283-5.
9. Granich GG, Kobayashi GS, Krogstad DJ. Sensitive high-pressure liquid Chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother. 1986; 29:5848.
10. Kirsh R, Goldstein R, Tarloff J et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988; 158:1065-70.
11. Caillot D, Chavanet P, Casasnovas O et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis. 1992; 11:722-5.
12. Chavanet PY, Carry I, Charlier N et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ. 1992; 305:921-5.
13. Caillot D, Reny G, Solary E et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother. 1994; 33:603-13.
14. Vita E, Schroeder DJ. Intralipid in prophylaxis of amphotericin B nephrotoxicity. Ann Pharmacother. 1994; 28:1182-3.
15. Gates C, Pinney RJ. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther. 1993; 18:147-53.
16. Mitrano FP, Outman WR, Baptista RJ et al. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4 °C for 35 days. Am J Hosp Pharm. 1991; 48:2635-7.
17. Lee MD, Hess MM, Boucher BA et al. Stability of amphotericin B in 5% dextrose injection stored at 4 or 25 °C for 120 hours. Am J Hosp Pharm. 1994; 51:394-6.
18. Wiest DB, Maish WA, Garner SS et al. Stability of amphotericin B in four concentrations of dextrose injection. Am J Hosp Pharm. 1991; 48:2430-3.